Background: The use of anti-EGFR monoclonal antibodies (MoAbs) is restricted in Europe to RAS wild-type metastatic colorectal cancer (mCRC) patients. While up today these targeted agents have been mainly chosen as salvage treatment in later lines, their use in first-line in combination with chemotherapy is highly debated. Methods: MEDLINE/PubMed, Cochrane Library, ASCO University, ESMO/ECCO conferences were searched for randomized controlled trials (RCTs) comparing first-line anti-EGFR MoAbs cetuximab or panitumumab plus chemotherapy to chemotherapy alone or with bevacizumab in patients with RAS wild-type colorectal cancer. Data extraction was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Results: Seven eligible RCTs were identified. In the overall RAS wild-type population (N = 2719), anti-EGFR MoAbs significantly improved OS (HR = 0.81; 95%CI, 0.71-0.92; p = 0.002), PFS (HR = 0.77; 95%CI, 0.60-0.98; p = 0.03) and objective response rate (ORR) (RR = 1.33; 95%CI, 1.09-1.62; p = 0.004). The addition of an anti-EGFR MoAb to chemotherapy alone improved PFS (p< 0.001) and ORR (p< 0.001) with a trend toward longer OS (p = 0.07). As compared to bevacizumab, anti-EGFR MoAbs significantly improved OS (HR = 0.80; 95%CI, 0.69-0.92; p = 0.003), but not PFS (HR = 0.94; 95%CI, 0.74-1.19; p = 0.59) or ORR (RR = 1.10; 95%CI, 0.97-1.25; p = 0.12). No significant differences were found with respect to the chemotherapy backbone (oxaliplatin- versus irinotecan-based). Conclusions: The choice of an anti-EGFR MoAb as first-line biologic is a valid option in RAS wild-type patients candidate to a doublet with infusional 5-FU. While attempting to further refine molecular selection, clinical considerations are crucial in planning the treatment strategy.

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer : a systematic review and meta-analysis / F. Pietrantonio, C. Cremolini, F. Petrelli, M. Di Bartolomeo, F. Loupakis, C. Maggi, C. Antoniotti, F. de Braud, A. Falcone, R. Iacovelli. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 96:1(2015 Oct), pp. 156-166. [10.1016/j.critrevonc.2015.05.016]

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer : a systematic review and meta-analysis

F. Pietrantonio
;
F. Petrelli;M. Di Bartolomeo;C. Maggi;F. de Braud;
2015-10

Abstract

Background: The use of anti-EGFR monoclonal antibodies (MoAbs) is restricted in Europe to RAS wild-type metastatic colorectal cancer (mCRC) patients. While up today these targeted agents have been mainly chosen as salvage treatment in later lines, their use in first-line in combination with chemotherapy is highly debated. Methods: MEDLINE/PubMed, Cochrane Library, ASCO University, ESMO/ECCO conferences were searched for randomized controlled trials (RCTs) comparing first-line anti-EGFR MoAbs cetuximab or panitumumab plus chemotherapy to chemotherapy alone or with bevacizumab in patients with RAS wild-type colorectal cancer. Data extraction was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Results: Seven eligible RCTs were identified. In the overall RAS wild-type population (N = 2719), anti-EGFR MoAbs significantly improved OS (HR = 0.81; 95%CI, 0.71-0.92; p = 0.002), PFS (HR = 0.77; 95%CI, 0.60-0.98; p = 0.03) and objective response rate (ORR) (RR = 1.33; 95%CI, 1.09-1.62; p = 0.004). The addition of an anti-EGFR MoAb to chemotherapy alone improved PFS (p< 0.001) and ORR (p< 0.001) with a trend toward longer OS (p = 0.07). As compared to bevacizumab, anti-EGFR MoAbs significantly improved OS (HR = 0.80; 95%CI, 0.69-0.92; p = 0.003), but not PFS (HR = 0.94; 95%CI, 0.74-1.19; p = 0.59) or ORR (RR = 1.10; 95%CI, 0.97-1.25; p = 0.12). No significant differences were found with respect to the chemotherapy backbone (oxaliplatin- versus irinotecan-based). Conclusions: The choice of an anti-EGFR MoAb as first-line biologic is a valid option in RAS wild-type patients candidate to a doublet with infusional 5-FU. While attempting to further refine molecular selection, clinical considerations are crucial in planning the treatment strategy.
Bevacizumab; Cetuximab; Colorectal cancer; Overall survival; Panitumumab; Randomized clinical trials; Oncology; Hematology; Geriatrics and Gerontology
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1040842815001146-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.7 MB
Formato Adobe PDF
1.7 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/425455
Citazioni
  • ???jsp.display-item.citation.pmc??? 27
  • Scopus 51
  • ???jsp.display-item.citation.isi??? 51
social impact